Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals (CSE:AGN) announces upcoming phase 2b chronic cough study of Ifenprodil

John Ballem  January 9, 2023

Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil

GlobeNewswire January 9, 2023

Algernon Pharmaceuticals forms Algernon NeuroScience subsidiary to advance DMT stroke program

TheNewsWire January 4, 2023

Algernon Pharmaceuticals (CSE:AGN) announces private subsidiary and SEC filing

Trevor Abes  January 3, 2023

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company's Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering

GlobeNewswire January 3, 2023

Algernon (CSE:AGN) receives FDA Orphan Drug Designation for Ifenprodil to treat Idiopathic Pulmonary Fibrosis

John Ballem  December 5, 2022

Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

GlobeNewswire December 5, 2022

Algernon Pharmaceuticals (CSE:AGN) screens first subject in Phase 1 DMT Human Stroke Study

Jonathon Brown November 16, 2022

Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

GlobeNewswire November 16, 2022

Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video

Newsfile November 8, 2022

Algernon Pharmaceuticals (CSE:AGN) enters into a clinical trial with Yale University for a DMT Phase 2 Depression study

Jonathon Brown October 24, 2022

Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study

GlobeNewswire October 24, 2022

Algernon Pharmaceuticals Announces Dr. Rick Strassman author of "DMT: The Spirit Molecule" to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference

GlobeNewswire October 14, 2022

Algernon Pharmaceuticals (CSE:AGN) receives C$450K cash refund from Australian research program

Azuka Onwuka September 21, 2022

Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program

GlobeNewswire September 21, 2022

Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF

GlobeNewswire September 19, 2022

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

GlobeNewswire September 12, 2022

Algernon (CSE:AGN) secures lead sponsorship of 2022 Wonderland Psychedelic Conference in Miami

Shoran Devi September 8, 2022

Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami

GlobeNewswire September 8, 2022

Microdose Announces Algernon Pharmaceuticals as Wonderland's Headline Sponsor

Newsfile September 8, 2022